Showing results (221-230 of 245) with videos related to

Sort By:
Pageof 25
European Heart Journal|August 23, 2021
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKDGiulio G Stefanini, Carlo Briguori, Davide Cao, et al.
The New England Journal of Medicine|November 10, 2025
Beta-Blockers after Myocardial Infarction with Normal Ejection FractionAnna Meta Dyrvig Kristensen, Xavier Rossello, Dan Atar, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 24, 2022
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKDPayam Dehghani, Davide Cao, Usman Baber, et al.
American Heart Journal|January 31, 2025
Characterizing high-risk enrollment criteria and impact on clinical outcomes in a large randomized clinical trial: Insights from the TWILIGHT trialPhilippe Gabriel Steg, Johny Nicolas, Usman Baber, et al.
Journal of the American College of Cardiology|August 17, 2023
Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary InterventionsGuiomar Mendieta, Shamir Mehta, Usman Baber, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|August 18, 2022
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG studyGennaro Sardella, Frans J Beerkens, George Dangas, et al.
JACC. Cardiovascular Interventions|October 25, 2023
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary InterventionDominick J Angiolillo, Davide Cao, Samantha Sartori, et al.
Circulation|October 27, 2024
Derivation and Validation of the PRECISE-HBR Score to Predict Bleeding After Percutaneous Coronary InterventionFelice Gragnano, David van Klaveren, Dik Heg, et al.
Lancet (London, England)|April 3, 2020
Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trialMichael Böhm, Kazuomi Kario, David E Kandzari, et al.
JACC. Cardiovascular Interventions|January 16, 2022
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT SubstudyMauro Chiarito, Usman Baber, Davide Cao, et al.
Pageof 25